Invitrogen extended its partnership with Chroma Therapeutics to use its SelectScreen™ platform for biochemical screening of Chroma’s multitargeted kinase inhibitors. The work will be conducted at Invitrogen’s Paisley, Scotland facility.
SelectScreen™ profiling and screening service integrates enzyme collections and cell lines with bioassay technologies to accelerate drug discovery programs. “The SelectScreen collection of assays has been assembled to address therapeutically relevant targets, phylogenetic diversity, and key signaling pathways, all of which are of interest to companies developing kinase inhibiting compounds,” says Nick Ecos, vp and GM of Invitrogen’s discovery sciences business.
